236 related articles for article (PubMed ID: 11851027)
1. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis.
van de Wyngaert FA; Beguin C; D'Hooghe MB; Dooms G; Lissoir F; Carton H; Sindic CJ
Acta Neurol Belg; 2001 Dec; 101(4):210-6. PubMed ID: 11851027
[TBL] [Abstract][Full Text] [Related]
2. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
4. [Use of mitoxantrone in early multiple sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year].
Ory S; Debouverie M; Le Page E; Pelletier J; Malikova I; Gout O; Roullet E; Vermersch P; Edan G
Rev Neurol (Paris); 2008 Dec; 164(12):1028-34. PubMed ID: 18808781
[TBL] [Abstract][Full Text] [Related]
5. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety.
Zipoli V; Portaccio E; Hakiki B; Siracusa G; Sorbi S; Amato MP
J Neurol Sci; 2008 Mar; 266(1-2):25-30. PubMed ID: 17870094
[TBL] [Abstract][Full Text] [Related]
6. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP;
Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900
[TBL] [Abstract][Full Text] [Related]
7. Rationale for the use of mitoxantrone in multiple sclerosis.
Edan G; Morrissey S; Le Page E
J Neurol Sci; 2004 Aug; 223(1):35-9. PubMed ID: 15261558
[TBL] [Abstract][Full Text] [Related]
8. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Vollmer T; Panitch H; Bar-Or A; Dunn J; Freedman MS; Gazda SK; Campagnolo D; Deutsch F; Arnold DL
Mult Scler; 2008 Jun; 14(5):663-70. PubMed ID: 18424479
[TBL] [Abstract][Full Text] [Related]
9. Defining interferon beta response status in multiple sclerosis patients.
Rudick RA; Lee JC; Simon J; Ransohoff RM; Fisher E
Ann Neurol; 2004 Oct; 56(4):548-55. PubMed ID: 15389896
[TBL] [Abstract][Full Text] [Related]
10. [Cognitive impact of mitoxantrone and methylprednisolone in multiple sclerosis: an open label study].
Zéphir H; de Sèze J; Dujardin K; Dubois G; Cabaret M; Bouillaguet S; Ferriby D; Stojkovic T; Vermersch P
Rev Neurol (Paris); 2008 Jan; 164(1):47-52. PubMed ID: 18342057
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mitoxantrone, as an initial therapy, in multiple sclerosis: experience in an Indian tertiary care setting.
Singhal BS; Geeta S; Hundalani SG; Menon S
Neurol India; 2009; 57(4):418-23. PubMed ID: 19770542
[TBL] [Abstract][Full Text] [Related]
12. High-dose methylprednisolone infusions in relapsing and in chronic progressive multiple sclerosis patients. One year follow-up.
Bergamaschi R; Versino M; Raiola E; Citterio A; Cosi V
Acta Neurol (Napoli); 1993 Feb; 15(1):33-43. PubMed ID: 8456594
[TBL] [Abstract][Full Text] [Related]
13. [Long-term effects of glatiramer acetate in multiple sclerosis].
Brochet B
Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
[TBL] [Abstract][Full Text] [Related]
14. Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS.
Smith D
J Neurol Sci; 2004 Aug; 223(1):73-9. PubMed ID: 15261565
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Wolinsky JS; Narayana PA; O'Connor P; Coyle PK; Ford C; Johnson K; Miller A; Pardo L; Kadosh S; Ladkani D;
Ann Neurol; 2007 Jan; 61(1):14-24. PubMed ID: 17262850
[TBL] [Abstract][Full Text] [Related]
16. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
18. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN.
Patti F; Amato MP; Filippi M; Gallo P; Trojano M; Comi GC
J Neurol Sci; 2004 Aug; 223(1):69-71. PubMed ID: 15261564
[TBL] [Abstract][Full Text] [Related]
19. A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.
Martinelli V; Rocca MA; Annovazzi P; Pulizzi A; Rodegher M; Martinelli Boneschi F; Scotti R; Falini A; Sormani MP; Comi G; Filippi M
Neurology; 2009 Dec; 73(22):1842-8. PubMed ID: 19949030
[TBL] [Abstract][Full Text] [Related]
20. Use of low-dose mitozantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status.
Ostberg A; Pittas F; Taylor B
Intern Med J; 2005 Jul; 35(7):382-7. PubMed ID: 15958106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
